Structure Therapeutics (GPCR) Stock Price, News & Analysis

Company Overview

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $24.11 to $24.71
• 50-Day Range: $14.15 to $27.55
• 52-Week Range: $13.22 to $62.74
• Volume: 267,802 shs
• Average Volume: 932,263 shs
• Market Capitalization: $1.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $79.86
• Consensus Rating: Buy

Structure Therapeutics Stock Analysis - MarketRank™

Structure Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 666th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Structure Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Structure Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Structure Therapeutics is -33.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Structure Therapeutics is -33.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Structure Therapeutics has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.78% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Structure Therapeutics has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Structure Therapeutics does not currently pay a dividend.

Dividend Growth

Structure Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.78% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Structure Therapeutics has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.10

News Sentiment

Structure Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Structure Therapeutics this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.43% of the stock of Structure Therapeutics is held by insiders.

Percentage Held by Institutions

91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GPCR Stock Analysis - Frequently Asked Questions

How have GPCR shares performed this year?

Structure Therapeutics' stock was trading at $27.12 at the beginning of 2025. Since then, GPCR stock has decreased by 9.5% and is now trading at $24.55.
View the best growth stocks for 2025 here.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. (NASDAQ:GPCR) released its earnings results on Thursday, May, 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.03.

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' top institutional shareholders include Wellington Management Group LLP (13.59%), Vestal Point Capital LP (3.12%), Driehaus Capital Management LLC (2.22%) and Federated Hermes Inc. (2.04%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Structure Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GPCR
• CIK: 1888886
• Web: www.structuretx.com
• Phone: 628-229-9277
• Fax: N/A
• Employees: 136
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $79.86
• High Stock Price Target: $118.00
• Low Stock Price Target: $50.00
• Potential Upside/Downside: +225.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-89,620,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -16.37%
• Return on Assets: -15.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.63
• Quick Ratio: 27.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.77 per share
• Price / Book: 2.51

Miscellaneous

• Outstanding Shares: 57,343,000
• Free Float: 51,861,000
• Market Cap: $1.41 billion
• Optionable: Optionable
• Beta: -1.69